کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2537177 | 1559183 | 2006 | 8 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Effect of YM-254890, a specific Gαq/11 inhibitor, on experimental peripheral arterial disease in rats Effect of YM-254890, a specific Gαq/11 inhibitor, on experimental peripheral arterial disease in rats](/preview/png/2537177.png)
The protective effect of YM-254890, a specific Gαq/11 inhibitor, on laurate-induced peripheral arterial disease in rats was compared with those of prostaglandin E1 (PGE1), beraprost, and clopidogrel. YM-254890 inhibited ADP-induced ex vivo rat platelet aggregation at a dose of 3 μg/kg. Furthermore, YM-254890 strongly inhibited phenylephrine-, serotonin- and endothelin-1-induced contractions in the rat aorta, and improved dermal blood flow after the laurate injection. The intra-arterial single bolus administration of YM-254890 15 min after the laurate injection dose-dependently inhibited the progression of the lesion, with significance, at 3 μg/kg without affecting systemic blood pressure. PGE1 and beraprost, when administered before the laurate injection, were effective, but their potencies were less than that of YM-254890. Clopidogrel significantly suppressed lesion progression when administered at 30 mg/kg twice a day for 3 days, which completely inhibited platelet aggregation. These results suggest that the local administration of YM-254890 may be useful for treating peripheral arterial disease.
Journal: European Journal of Pharmacology - Volume 536, Issues 1–2, 24 April 2006, Pages 154–161